首页> 外文期刊>Robotics and Machine Learning >Critical Outcome Technologies Inc. Initiates Preclinical Testing of AML Drug Candidates
【24h】

Critical Outcome Technologies Inc. Initiates Preclinical Testing of AML Drug Candidates

机译:Critical Outcome Technologies Inc.启动AML候选药物的临床前测试

获取原文
获取原文并翻译 | 示例

摘要

Critical Outcome Technologies Inc. (COTI) (TSX VENTURE:COT) announced that it has completed nsynthesis of compounds from its acute myelogenous leukemia (AML) program and has initiated nconfirmatory preclinical tests, representing an important step forward in the development of these npotential drug candidates.
机译:Critical Outcome Technologies Inc.(COTI)(TSX VENTURE:COT)宣布已完成其急性骨髓性白血病(AML)计划中化合物的合成,并启动了非确证性临床前测试,代表着开发这些潜在药物的重要一步候选人。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号